OLYMPUS MYOGLOBIN IMMUNOTURBIDMETRIC REAGENT

K984145 · Olympus Diagnostica GmbH · DDR · Dec 23, 1998 · Immunology

Device Facts

• Record ID: K984145
• Device Name: OLYMPUS MYOGLOBIN IMMUNOTURBIDMETRIC REAGENT
• Applicant: Olympus Diagnostica GmbH
• Product Code: DDR · Immunology
• Decision Date: Dec 23, 1998
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 866.5680
• Device Class: Class 2

Intended Use

The Olympus Myoglobin reagent is intended to be utilized for the quantitative determination of myoglobin in human serum on Olympus analyzers. Measurement of myoglobin aids in the rapid diagnosis of heart or renal disease.

Device Story

Olympus Myoglobin Reagent is an in vitro diagnostic reagent for use on Olympus clinical chemistry analyzers. It utilizes turbidimetric immunoassay technology to measure myoglobin concentrations in human serum samples. The device is operated by laboratory professionals in clinical settings. The analyzer processes the sample, performs the turbidimetric measurement, and provides a quantitative result. This output assists clinicians in the rapid assessment and diagnosis of heart or renal disease, facilitating timely clinical decision-making and patient management.

Clinical Evidence

No clinical data provided; bench testing only.

Technological Characteristics

Turbidimetric immunoassay reagent for use on automated clinical chemistry analyzers. Designed for quantitative analysis of myoglobin in human serum.

Indications for Use

Indicated for quantitative determination of myoglobin in human serum to aid in diagnosis of heart or renal disease.

Regulatory Classification

Identification

A myoglobin immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the myoglobin (an oxygen storage protein found in muscle) in serum and other body fluids. Measurement of myoglobin aids in the rapid diagnosis of heart or renal disease.

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other.

DEC 23 1998

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Laura Storms-Tyler Director, Requlatory Affairs Olympus Diagnostica GMBH C/O Olympus Corp. of America Two Corporate Center Drive Melville, NY 11747

K984145 Re: Trade Name: Olympus Myoglobin Turbidimetric Reagent Requlatory Class: II Product Code: DDR November 17, 1998 Dated: Received: November 19, 1998

Dear Ms. Storms-Tyler:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or requlations.

{1}------------------------------------------------

Paqe 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) Additionally, for questions on the promotion and 594-4588. advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number [phone] or [phone], or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven Butman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

## Indications for Use Statement

## 510(k) Number (if known): K984145

Device Name:

Olympus Myoglobin Reagent

Indications for Use:

The Olympus Myoglobin reagent is intended to be utilized for the quantitative determination of myoglobin in human serum on Olympus analyzers. Measurement of myoglobin aids in the rapid diagnosis of heart or renal disease.

## (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

| Prescription Use (per 21 CFR 81.109) | <div style="display:inline-block; vertical-align:middle;"> <img alt="Checkmark" src="" style="width:15px;height:15px;"/> </div> | OR | Over-the Counter Use (Optional Format 1-2-96) |
|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|----|-----------------------------------------------|
|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|----|-----------------------------------------------|

Veronica Q. Calvin for awm

(Division Sign Off)

Division of Clinical Laboratory Devices

510(k) Number: K984145